[ET Net News Agency, 9 September 2019] Citi Research lowered its target price for China
Resources Medical (01515) to HK$6.6 from HK$12.5 and downgraded its rating to "neutral"
from "buy".
The research house adjusted the sales trend on for-profit, sponsorship and IOT hospitals
and 2019-2021 EPS were changed by -17%,-21% and -24% respectively.
Citi is cautious on the existing hospitals' operation under government budgeting
control, and new hospital acquisitions remained slower than expected. It also cut down the
hospital revenue in its DCF model to reflect the slow M&A. (KL)
|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01515 CR MEDICAL
Nominal 
3.770 -0.040 (-1.050%) Others
09/09/2019 17:17
{I-bank focus}Citi downgrades CR Medical (01515) to HK$6.6
| Remark: | Real time quote last updated: 16/04/2024 14:21 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service |